|
Addition of Thiazolidinediones to GLUCOVANCE Therapy For patients not adequately controlled on GLUCOVANCE, a thiazolidinedione can be added to GLUCOVANCE therapy. When a thiazolidinedione is added to GLUCOVANCE therapy, the current dose of GLUCOVANCE can be continued and the thiazolidinedione initiated at its recommended starting dose. For patients needing additional glycemic control, the dose of the thiazolidinedione can be increased based on its recommended titration schedule. The increased glycemic control attainable with GLUCOVANCE plus a thiazolidinedione may increase the potential for hypoglycemia at any time of day. In patients who develop hypoglycemia when receiving GLUCOVANCE and a thiazolidinedione, consideration should be given to reducing the dose of the glyburide component of GLUCOVANCE. As clinically warranted, adjustment of the dosages of the other components of the antidiabetic regimen should also be considered. Text Continues Below
Specific Patient Populations GLUCOVANCE is not recommended for use during pregnancy or for use in pediatric patients. The initial and maintenance dosing of GLUCOVANCE should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Any dosage adjustment requires a careful assessment of renal function. Generally, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of GLUCOVANCE to avoid the risk of hypoglycemia. Monitoring of renal function is necessary to aid in prevention of metformin-associated lactic acidosis, particularly in the elderly. (See WARNINGS.) HOW SUPPLIED GLUCOVANCE ® (Glyburide and Metformin HCl Tablets)
GLUCOVANCE 1.25 mg/ 250 mg tablet is a pale yellow, capsule-shaped, bevel edged, biconvex film-coated tablet with "BMS" debossed on one side and "6072" debossed on the opposite side. Page: << Prev | 1 | 2 | 3 | 4 | Next >>
|
.gif)
